Italia markets close in 3 hours 30 minutes

UCB SA (UCB.BR)

Brussels - Brussels Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
87,86-0,80 (-0,90%)
Al 01:44PM CEST. Mercato aperto.

UCB SA

Allée de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
https://www.ucb.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno8.006

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Jean-Christophe TellierCEO & Exec. Director4,26MN/D1959
Ms. Sandrine Dufour CFAExec. VP & CFON/DN/D1966
Ms. Kirsten Lund-JurgensenExec. VP of Supply & Technology SolutionsN/DN/D1959
Dr. Dhavalkumar D. Patel M.D., Ph.D.Exec. VP & Chief Scientific OfficerN/DN/D1961
Mr. William J. SilbeyExec. VP & Gen. CounselN/DN/D1959
Mr. Jean-Luc FleurialExec. VP & Chief HR OfficerN/DN/D1965
Prof. Iris Low-FriedrichExec. VP, Chief Medical Officer and Head of Devel. & Medical Patient Value PracticesN/DN/D1960
Mr. Emmanuel CaeymaexExec. VP of Immunology Solutions & Head of USN/DN/D1969
Mr. Charl van ZylExec. VP of Neurology Solutions & Head of EU/InternationalN/DN/D1967
Ms. Caroline VancoillieChief Accounting Officer & CFO of Patient Value FunctionsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Governance aziendale

L'ISS Governance QualityScore di UCB SA al 1 maggio 2022 è 4. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 6; diritti degli azionisti: 1; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.